⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

September 16, 2024

Figure S6 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors

Martina S.J. McDermott Neil A. O’Brien Benjamin Hoffstrom KeWei Gong Ming Lu Jun Zhang Tong Luo Min Liang Weiping Jia Jenny J. Hong Kevin Chau Simon Davenport Bin Xie Michael F. Press Richard Panayiotou Abram Handly‐Santana Joan S. Brugge Leonard Presta John A. Glaspy Dennis J. Slamon

View at Publisher

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Supplemental Figure S6: In vivo efficacy of a range of doses of CLDN6-23-ADC in M202 xenograft models. ADC dosing is IV QW as indicated by the arrows

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

McDermott et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522d76 https://doi.org/10.1158/1078-0432.27030349.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors2024
2Figure S3 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors2024
3Figure S4 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors2024
4Figure S1 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors2024
5Figure S7 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors2024
6Figure S2 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors2024
7Figure S8 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors2024
8Data from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors2024